Research ArticleAccepted Article
Towards Defining Primary and Secondary Non-Response in Rheumatoid Arthritis Patients Treated with Anti-TNFs: Results from the BioTRAC and OBRI Registries
Edward Keystone, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Melissa Stutz, John S. Sampalis, Francois Nantel, Karina Maslova and Claire Bombardier
The Journal of Rheumatology July 2019, jrheum.190102; DOI: https://doi.org/10.3899/jrheum.190102
Edward Keystone
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Emmanouil Rampakakis
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Mohammad Movahedi
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Angela Cesta
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Melissa Stutz
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
John S. Sampalis
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Francois Nantel
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Karina Maslova
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Claire Bombardier
The Rebecca MacDonald Centre for Arthritis, Mount Sinai Hospital, Toronto, Ontario, Canada; JSS Medical Research Inc., St-Laurent, Quebec, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Janssen Inc., Toronto, Ontario, Canada; University of Toronto, Department of Medicine (DMO) and Institute of Health Policy, Management, and Evaluation (IHPME), Toronto, Ontario, Canada; Mount Sinai Hospital, Division of Rheumatology, Toronto, Ontario, Canada. Conflicts of interest: EK has received sources of funding for research from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis; has a consulting agreement/ is a member of an advisory board for Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz; and received speaker honoraria agreements for Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB. AC, MM, and CB are employees at OBRI which was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. ER, MS, and JSS are employees at JSS Medical Research, the CRO mandated to manage BioTRAC. FN is an employee at Janssen. KM is a former employee of Janssen. Funding: This work was supported by Janssen Inc. partially (medical writing services). OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Hospital Janssen, Pfizer, Roche, Sanofi and UCB. Address correspondence to Dr. Edward Keystone, The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Towards Defining Primary and Secondary Non-Response in Rheumatoid Arthritis Patients Treated with Anti-TNFs: Results from the BioTRAC and OBRI Registries
Edward Keystone, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Melissa Stutz, John S. Sampalis, Francois Nantel, Karina Maslova, Claire Bombardier
The Journal of Rheumatology Jul 2019, jrheum.190102; DOI: 10.3899/jrheum.190102
Accepted manuscript
Towards Defining Primary and Secondary Non-Response in Rheumatoid Arthritis Patients Treated with Anti-TNFs: Results from the BioTRAC and OBRI Registries
Edward Keystone, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Melissa Stutz, John S. Sampalis, Francois Nantel, Karina Maslova, Claire Bombardier
The Journal of Rheumatology Jul 2019, jrheum.190102; DOI: 10.3899/jrheum.190102